TheraRadar
Data updated: May 26, 2026

LUZU (luliconazole)

Cytochrome P450 2C19 Inhibitors
Infectious Disease Approved 2013-11-14

LUZU is indicated for the treatment of Tinea Pedis; Tinea Cruris; Tinea Corporis.

Source: FDA Label • BAUSCH • Azole Antifungal

How LUZU Works

Luliconazole is an azole antifungal that works by inhibiting the enzyme lanosterol 14-alpha-demethylase. This inhibition disrupts the biosynthesis of ergosterol, a critical component of the fungal cell membrane, leading to fungal cell death.

2
Indications
--
Phase 3 Trials
12
Years on Market

Details

Status
Prescription
First Approved
2013-11-14
Patent Cliff
2034

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
TOPICAL
Dosage Forms
CREAM

Companies

Active Ingredient: LULICONAZOLE

LUZU Approval History

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
5 FDA actions from 2013 to 2018 · 1 indication expansions
Feb 2018 SUPPL
Efficacy
Feb 2017 SUPPL
Label · Labeling
Jun 2016 SUPPL
Mfg · Manufacturing (CMC)

What LUZU Treats

3 indications

LUZU is approved for 3 conditions since its original approval in 2013. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Tinea Pedis
  • Tinea Cruris
  • Tinea Corporis
Source: FDA Label

LUZU Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to LUZU

3 of 17

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

CLOTIC
CLOTRIMAZOLE
3 shared
CARWIN PHARM ASSOC
CLOTRIMAZOLE
CLOTRIMAZOLE
3 shared
Hikma
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE
BETAMETHASONE DIPROPIONATE
3 shared
GLENMARK SPECLT
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

LUZU FDA Label Details

Indications & Usage

FDA Label (PDF)

LUZU is indicated for the treatment of Tinea Pedis; Tinea Cruris; Tinea Corporis.

View full patent landscape →
4 OB patents · 4 families · 38 international docs across 8 countries

LUZU Patents & Exclusivity

Latest Patent: Apr 2034

Patents (4 active)

US8980931 Expires Apr 28, 2034
US9012484 Expires Sep 6, 2033
US9453006 Expires Sep 6, 2033
US9199977 Expires Sep 6, 2033
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for LUZU

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2034
  • 4 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • 17 similar drugs
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.